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INTRODUCTION 
 
Snake bite is an acute life threatening medical emergency  
throughout the world , especially in tropical countries like India. It is one 
of the preventable health hazards of people especially in rural areas of 
tropical and subtropical countries. There are around 3500 species of 
snakes in the world and about 300 species are found in India among 
which 52 are venomous .Only 4 species are commonly encountered in  
India. They are Naja naja (Indian cobra), Bungarus caeruleus (Indian 
Krait), Daboia  russelii (Russells’ viper), Echis carinatus (saw scaled    
viper). 
Cobra and common krait belong to family Elapidae. Russells’ viper 
and saw scaled viper belong to family Viperidae. Elapidae group cause 
neuromuscular paralysis leading to death by respiratory paralysis and  
Viperidae group causes hemorrhagic syndromes. Snake venom contain a 
cocktail of many components like enzymes, polynucleotides, toxins,   
carbohydrates , metals , lipids , biogenic amines. 
      The treatment of snake bite includes the care of the bitten site and 
ASV administration. Anti Snake Venom (ASV) administration is the only 
definitive treatment which acts by neutralising the circulating  venom in 
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the blood and tissue fluid .Early administration of ASV is  therefore es-
sential to neutralise the maximum circulating venom before it is fixed in 
the tissues. ASV completely reverses all clinical manifestations of sys-
temic envenomation. Each 1ml of ASV neutralises 0.60mg of dried Indi-
an Cobra venom; 0.45mg of dried Common Krait venom; 0.60mg of 
dried Russell’s Viper venom; 0.45mg of dried Saw scaled viper venom. 
      Though there are many studies regarding the epidemiology and     
clinical profile of snake envenomation , at present only very few studies 
are available about the correlation between the timing of ASV             
administration and reduction of complications in snake bite                  
envenomation. 
         The present study was undertaken to evaluate whether early        
administration of ASV increases its efficacy in reducing the               
complications in snake bite cases. 
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AIM AND OBJECTIVES 
 
AIM :  
The aim of the study is to evaluate whether early administration of 
ASV increases its efficacy in reducing the complications in snake bite 
cases. 
OBJECTIVES: 
 To study the impact of time interval between the snake bite and 
ASV administration in reducing the complications in snake bite 
envenomation. 
 To determine the  “GOLDEN TIME” - OPTIMUM  “BITE TO 
NEEDLE TIME” of ASV administration in reversing the         
complications of snake bite envenomation. 
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REVIEW OF LITERATURE 
 
INTRODUCTION :  
Snakes were worshipped, respected, admired and feared by early 
civilizations. The ancient Egyptians had prescribed treatments for snake 
bites in the Thirteenth Dynasty in The Brooklyn Papyrus that included 
seven venomous species common to the region today like the horned    
vipers. 
In Judaism, the Nehushtan ( a pole with a snake made of copper 
fixed upon it) was considered as a divinely instrument of God that brings 
healing to Jews bitten by venomous snakes while they were wandering in 
the desert after their exodus from Egypt. Snakebites were also a means of 
execution in some cultures  like medieval Europe where a form of capital 
punishment was to throw people into a snake pits, leaving the people die 
from multiple venomous bites. Snake bites were also a form of suicide , 
like in the case of Egyptian queen Cleopatra , who reportedly died of bite 
from an Egyptian Cobra after hearing of Mark Antony’s death. 
      Snake bite is an acute life threatening medical emergency throughout 
the world, especially in the tropical countries like India .Snake bite       
estimates vary from 1.2 to 5.5 million, about 2.5 million envenoming and 
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20,000 to 1,25,000 deaths per year. The data is not precise since reporting 
is not mandatory in many parts of the world. Most snake envenomings 
and fatalities occur in Sub-Saharan Africa, South Asia, Southeast Asia. 
India reports the most snakebite deaths than any other country. There are 
nearly  3500 species of snakes in the world. Snakes are found in every 
continent except Antarctica. About 300 species are found in India among 
which 52 are venomous .Only 4 species are commonly encountered in In-
dia . 
They are : 
1. Naja naja (Indian Cobra) , 
2. Bungarus caeruleus (Indian Krait) , 
3. Daboia russelii (Russells’ Viper) ,  
4. Echis carinatus (Saw scaled Viper) . 
The snakes found in India belong to three families, which are : 
Elapidae , Viperidae , hydrophidae . 
1. Elapidae includes Common Cobra , King Cobra and Krait . 
2. Viperidae includes Russell’s Viper ,Pit Viper and saw scaled viper. 
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3. Hydrophidae includes sea snakes . 
 Viperidae group produces haemorrhagic syndromes , 
 Elapidae group produces neuromuscular paralysis.  
SAW SCALED VIPER (ECHIS CARINATUS) 
1. It is one to three feet long, head is subovate with short rounded 
snout, body is cylindrical, short ,covered with serrated flank 
scales. Neck is distinctly constricted.  It is pale brown or tawny 
with dark brown. A cruciform or arrow shaped mark is seen on 
the head. 
2. It flourishes in hot and humid climate in the costal regions of   In-
dia. 
3. It is diurnal in habit, alert and capable of quick movement when 
necessary . 
4. It hibernates in winter. 
5. It bites on smallest provocation with extremely rapid strike. 
6. It is viviparous and produces 3 to 15 off springs at a time . 
7. It injects 0.0046 gram of  venom at the time of bite. 
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RUSSELL’S VIPER : 
1. It is 3 to 5 feet long .The head is covered with small scales   with-
out shields. The length of fangs in an adult is 16 mm and curved. 
2. The body is massive, cylindrical, narrowed at both ends. 
3. The head is flat and triangular with short snout, large gold flecked 
eyes with vertical pupils and large open nostrils. 
4. Its belly is round with constricted neck. 
5. The typical rows of oval arranged in two rows is the              char-
acteristic of Russell’s Viper. 
6. The female produces 20 to 60 young ones usually around the 
month of June or July. 
7. It injects 63 mg  of venom at the time of bite . 
8. Its natural prey are mice, rats, lizards, frogs, birds and snakes. The 
young    snakes are cannibalistic. 
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COMMON KRAIT : 
1. Krait is the most poisonous snake. Its venom is 10 times more poi-
sonous than Cobra venom. 
2. It is 1 - 4 feet long with hexagonal vertebral scales, uniform white 
or red belly and narrow white crossbars on the back, the cross 
bars are absent near the head and neck region. 
3. The common krait resides in the vicinity of human habitat. 
4. The Krait is a nocturnal, terrestrial snake which enters the human 
dwelling in search of prey like  mice, rats, lizards. 
5. Common krait is considered as the most dangerous species of ven-
omous snake in the Indian subcontinent. 
6. Most bites occur during the months of June to December, due to 
cool climate the snakes linger in a person’s bedding in search of 
warmth . 
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COBRA  : 
1. Cobra bite occurs during day time .Cobra venom is cardiotoxic, 
neurotoxic, haematotoxic and cytotoxic.  
2. The fangs of cobra are  small and sharp. The venom is small   
molecular size hence rapidly absorbed into circulation. 
 
Non-poisonous Snakes 
1. RatSnake (Coluber  mucosus) 
2. Common Wolf Snake (Lycodon aulicus) 
3. Python (Python molurus molurus) 
4. Common Sand Boa (Eryx conicus) 
5. Bronze back tree snake (Dendrelaphis tristis) 
6. Common cat snake (Boiga trigonata 
7. Stripped keelback (Amphiesma stolata) 
8. Trinket (Elaphe helena) 
9. Water Snake (Checkered Keel Back) 
10. Earth Boa (Eryx johnii) 
11. Grass Snake (Macropisthodon plumbicolor) 
12. Banded Racer (Argyrogena fasciolatus) 
13. Common kukri snake (Oligodon amensis) 
14. Vine or Whip snake (Ahaetulla) 
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Figure 1: Common spectacled cobra (Naja naja): 
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Figure 2: North Indian or Oxus cobra (Naja oxiana) 
 
 
 
 
 
12 
 
 
Figure 3: Indo-Chinese spitting cobra (Naja siamensis 
)  
(a) Brown-coloured specimen 
   
(b) Black and white specimen with ill- defined spectacle  
marking on hood 
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Figure 4: Common krait (Bungarus caeruleus) 
 
(a) Sri Lankan specimen showing narrow white dorsal bands 
 
 
(b) Indian specimen showing pure white ventrals 
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Figure 5: Banded krait (Bungarus fasciatus)  
 
(a) Showing black and yellow bands 
 
 
  
(b) Showing circumferential black bands and blunt-tipped tail  
(scale in cms). 
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Figure 6: Western Russell’s viper (Daboia russelii) 
a  
(a) Specimen from southern India 
 
 
(b) Specimen from Sri Lanka 
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Figure 7: Eastern Russell’s vipers (Daboia siamensis) 
 
 
(a) Specimen from Myanmar 
  
(b) Specimen from Thailand 
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Figure 8: Saw-scaled vipers (Echis carinatus) 
 
(a) Echis carinatus carinatus Specimen from southern India 
 
 
(b) Echis carinatus carinatus Specimen from Sri Lanka 
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Figure 9: Hump-nosed viper (Hypnale hypnale) 
 
(a) Specimen from Sri Lanka              (b) Specimen from Sri Lanka  
                                                                           showing long fangs 
 
 
(c) Specimen from south western India 
 
(d) Specimen from south western India showing upturned snout 
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Figure 10. Identification of snake species 
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CIRCUMSTANCES OF SNAKE BITE AND THEIR PREVENTION: 
1. Grass cutting is the major situational source of bites. 
2. In rubber, coconut plantations, clearing the base of trees to apply 
manure leads to significant number of bites. 
3. Vegetable and fruit harvesting. 
4. Tea and coffee plantation workers face the risk of viper bites 
when picking the bushes. 
5. Walking in the night, barefooted or wearing open sandals without 
a torch accounts for a significant number of bites. 
6. Bathing in ponds, rivers, streams in the evening poses risks since 
Cobras and some other venomous species are good swimmers. 
7. Walking along the edge of waterways. 
PREVENTIVE MEASURES: 
1. Closed type footwear for walking at night along with a flashlight 
which is switched on!. 
2. Carrying a stick when grass cutting, fruit picking, clearing the tree 
base. 
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3. Paying close attention to the leaves and sticks on the ground while 
collecting wood. 
4. Keeping the rubbish and animal feeds away from the house since 
they may attract rats eventually followed by snakes. 
5. Avoiding a sleep on the ground. 
THE VENOM APPARATUS 
The venom glands of Elapidae and Viperidae are located behind 
the eye which are surrounded by compressor muscles. The venom duct 
opens at the base of fangs and the venom is transported to its tip by a   
canal like a hypodermic needle. 
In Elapidae, the fangs are situated on a relatively fixed maxilla at 
the front of mouth but in Viperidae, the fangs are located on a rotatable 
maxilla .In Colubridae, venom from the glands track down the grooves in 
the anterior surface of fangs at the posterior end of maxilla.  
Fangs allow the snake to introduce the venom deep into the tissues 
of its prey. In case of human bite, venom is usually injected                
subcutaneously or intramuscularly .Spitting cobras can squeeze the    
venom from their fangs producing a fine spray directed towards the eye 
of the victim. 
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Figure 11: Venom apparatus of an eastern Russell’s viper  
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CLINICAL SYMPTOMS : 
 Clinical symptoms and signs of snakebite victim depends upon : 
1. The species of snake  
2. Amount of injected venom   
3. Site of bite   
4. Dry or incomplete bite  
5. Multiple bites  
6. Whether snake is fed or not  
7. Time elapsed between the bite and ASV administration .  
      Patients may present with non specific symptoms related to anxiety 
like     palpitations, sweating ,tachycardia,  tachypnoea, elevated blood 
pressure . 
NEUROPARALYTIC SNAKE BITE ENVENOMATION : 
Patients present with typical symptoms within  30 minutes to 6 
hours of Cobra bite and 6 to 24 hours for Krait bite . 
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The patients present with : 
1. Drooping of eyelids (ptosis) ,  
2. Diplopia ( double vision) ,  
3. Dysarthria ,  
4. Dysphonia ,  
5. Dyspnoea ,  
6. Dysphagia  
7. Finally, paralysis of intercostal and skeletal muscles occur . 
8. Hypertension and tachycardia may be present  due to hypoxia . 
      Bedside lung function test can be done to identify impending respira-
tory failure . 
The tests are : 
1. SINGLE BREATH COUNT : number of digits counted in one 
exhalation - should be > 30 . 
2. BREATH HOLDING TIME : Breath held in inspiration - normal 
is  > 45 seconds. 
3. Ability to complete one sentence in one breath . 
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VASCULOTOXIC SNAKE BITE ENVENOMATION : 
Viper species produces vasculotoxic effects  which can be both lo-
cal and systemic manifestations . 
 LOCAL MANIFESTATIONS : 
These are more prominent in Russel’s Viper bite followed by Saw 
scaled Viper and least in Pit viper . 
The local manifestations are: 
1. local swelling  
2. Bleeding  
3. Blistering   
4. Necrosis  
5. Pain at the bite site  
6. Tender and enlarged local lymph node   
7. Severe swelling leading to compartment syndrome  
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  SYSTEMIC MANIFESTATIONS : 
1. Gingival bleeding 
2. Epistaxis  
3. Ecchymotic patches  
4. Haematemesis  
5. Hemoptysis  
6. Bleeding per rectum 
7. Subconjunctival haemorrhages  
8. Acute abdominal tenderness suggesting gastro-intestinal or retro 
peritoneal bleeding . 
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a) 
 
b) 
 
 c) 
Figure 12.  a) gum bleeding in Viper bite b) conjunctival edema  in Viper 
bite  c) Ptosis in neuroparalytic snakebite  
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a) 
 
b) 
 
Figure 13 . a) envenomed foot   b) snake bite marks on foot 
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Figure 14 . ‘‘Broken neck’’ sign observed in a 14-year-old girl bitten by a 
Russell’s viper in India. 
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LIFE THREATENING COMPLICATIONS : 
 AKI (ACUTE KIDNEY INJURY ) :  
Patients present with hematuria ,hemoglobinuria followed by       
oliguria and anuria . 
LONG TERM COMPLICATIONS OF SNAKEBITE (SEQUELAE) 
1. Chronic ulceration, osteomyelitis, arthritis may persist at the site of 
bite. 
2. Malignant transformation  (Marjolin’s ulcer) may occur in skin   
ulcers after  few years. 
3. Chronic kidney disease may occur after bilateral cortical necrosis . 
4. Chronic panhypopituitarism or diabetes insipidus may occur after 
Russell’s viper bites. 
5. Chronic neurological deficits may be present in patients who     
survive intracranial haemorrhages and thrombosis. 
6. Delayed psychological disturbances like depression, anxiety, post 
traumatic stress disorder may be present few years after snakebites. 
7. Chronic musculoskeletal disabilities like muscle wasting, stiff 
joints, impaired balance, fixed deformities may occur few years   
after snake bite. 
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OCCULT SNAKE BITE :  
Krait has nocturnal habitat and has fine slender  teeth , hence bite 
marks usually cannot be identified . Sometimes Krait bite victims may 
present in the early morning with paralysis with no other local signs 
.Patient will have the typical history of going to bed healthy at night 
,getting up in the morning with  severe epigastric pain and vomiting     
followed by neuroparalytic symptoms with no history of snake bite which 
can be mistaken for GB syndrome . Krait bite produces  descending    
neuroparalysis whereas GB syndrome produces ascending paralysis . 
DRY BITE : Bites by venomous species are not always accompanied by 
the injection of venom .It is called dry bite . 
VENOM COMPOSITION 
1. Snake venom is a complex mixture of proteins and peptides. The 
proteins   make up over 90% of the dry weight of the venom. 
2. Each venom contains enzymes ,non-enzymatic polypeptide toxins 
,non toxic proteins .  
3. Snake venom also contains inorganic cations such as calcium, 
magnesium, potassium, sodium, zinc, iron, cobalt, manganese 
and nickel. The metals in the venom are the catalysts for         
metal-based enzymatic reactions. 
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4. Some snake venom also contain carbohydrates, lipids, biogenic 
amines such as histamine, serotonin. 
ENZYMES : 
Nearly 26 different enzymes have been isolated from snake      
venoms. No single snake venom contains all of the enzymes. 
Proteolytic enzymes : 
Catalyze the breakdown of tissue proteins and peptides include 
peptide hydrolases, proteases, endopeptidases, peptidases, proteinases. 
The proteolytic enzymes have molecular weights between 20,000 and 
95,000. 
Collagenase : 
It is a specific kind of proteinase that digest collagen. This  activity 
has been demonstrated in the venoms of a number of species of crotalids 
and viperids. EDTA inhibits the collagenolytic effect. 
Hyaluronidase : 
It cleaves the internal glycoside bonds in certain  
mucopolysaccharides resulting in decrease in the viscosity of connective 
tissues. This allows the venom to penetrate the tissue .Hence it is called 
“spreading factor”. 
 
 
33 
 
Phospholipase A2  (PLA2): 
This enzyme is widely distributed in the tissues of animals, plants, 
bacteria. Mammalian PLA2  enzymes are involved in fertilization and 
cell proliferation.PLA2 interact with other toxins in the venom often  
resulting in synergistic activity. Phospholipase A2 damages the  
mitochondria, RBCs, leucocytes, platelets ,skeletal muscles vascular  
endothelium and produce presynaptic neurotoxic and opiate-like sedative 
effects . 
Fibrinolytic enzymes : 
There are two different classes of fibrinolytic enzymes, the   
metalloproteinases and the serine proteinases .They breakdown fibrin rich 
clots and help  to prevent further clot formation. Venoms of Viperidae 
,Elapidae contain procoagulant enymes which stimulate blood clotting 
with  formation of fibrin but the fibrin clot is broken down by the body’s 
own fibrinolytic system and produce consumption coagulopathy due to 
the depletion of clotting factors . 
Snake venom hemorrhagic metalloproteinases (SVMP) : 
They are the enzymes that disrupt the hemostatic system .They are 
of 4 types. P1 to P4.SVMP degrade proteins such as laminin , fibronectin, 
type 4 collagen, proteoglycans from the endothelial basal membrane;   
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degrade fibrinogen and Von Willibrand factor enhancing the hemorrhagic 
action and inhibits platelet aggregation . 
Acetylcholinesterase : 
It was first demonstrated in cobra venom widely distributed 
throughout the Elapid venoms. It catalyses the hydrolysis of acetylcholine 
to choline and acetic acid. 
RNase : 
It is present in some snake venoms in small amounts as the         
endopolynucleotidase RNase. It appears to have specificity towards      
pyrimidine-containing pyrimidyladenyl bonds in DNA. 
DNase : 
They act on DNA to produce predominantly tri- or higher            
oligonucleotides that terminate in 3’ monoesterified  phosphate . 
5’-Nucleotidase : 
It is a common constituent of all snake venoms .It is the most      
active phosphatase in snake venoms. It specifically hydrolyzes phosphate 
monoesters, which link with a 5’ position of DNA and RNA. The        
molecular weight is 10,000 
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Nicotinamide adenine dinucleotide  nucleotidase (NAD) : 
This enzyme catalyses the hydrolysis of the nicotinamide             
N-ribosidic linkage of NAD, yielding nicotinamide and adenosine         
diphosphate riboside. Nucleotidases function as ADP scavengers thereby 
acting as potent inhibitors of platelet aggregation.  
POLYPEPTIDES : 
Snake venom polypeptides are low-molecular weight proteins that 
do not have enzymatic activity. More than 80 polypeptides with        
pharmacological activity have been isolated from snake venoms.         
Disintegrins are a family of short cysteine- rich polypeptides divided into 
five subgroups based on the combination of length and number of         
disulfide bonds of polypeptides. Disintegrins comprise 40-100 amino   
acids. Disintegrins are released in venoms via proteolytic processes of 
metalloproteinases. Monomeric disintegrins vary from about 50 residues 
and four disulfide bonds to around 70 amino acid residues. Dimeric     
disintegrins are about 67 amino acids long and contain four intrachain  
disulfide linkages and two between-chain bonds. 
NEUROTOXINS : 
Bungarotoxin, cobrotoxin, crotoxin, taipoxin are neurotoxins which 
bind to acetylcholine receptors and damage the receptors . 
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Table 3.1. Nature of toxins, signs and symptoms of different snake bites. 
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Table 3.2 .Snake venom proteins and peptides of clinical importance. 
 
Table 3.3 Features of different snake bites. 
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Figure  15.  Pathophysiology of clinical spectrum in snake bite  
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FIRST AID MEASURES :  
1. History of snake bite should be checked and evidence of snake bite 
(fang marks, bleeding, swelling of bitten part) should be  noted . 
HISTORY : 
a. Ask questions about what the victim was doing at the time of  
bite. A precise history about the circumstance of the bite and the   
progression of local and systemic symptoms and signs is very 
important. 
b. Bite marks are of little importance in determining species. Many 
non-venomous species leave just two fang-like marks. Some    
species like krait leave no bite marks at all. Many species have 
more than two fangs, as they grow reserve fangs in case the main 
one break off. 
c. Determine the exact time of the bite which can give clue to the 
progression of any symptoms. In case, the patient reaches the  
hospital soon after the bite, he may have only few symptoms and 
signs even though a large amount of venom may have been       
injected. If the patient was bitten at night while asleep, it would 
be probably a krait. If bitten in a paddy field, a cobra or Russell’s 
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viper; if while swimming in water, a cobra;  if while tending fruit 
trees, a green pit viper. 
d. A common  and early symptom of systemic envenomation is 
vomiting. Patient should be asked about how much urine he has 
passed since the bite and about the colour of the urine. Patients 
who complain of drooping of eyelids, blurring of vision, double 
vision or sleepiness may have neurotoxic envenomation. 
e. The snake responsible should be identified where ever possible. If 
the victim had bring the snake to the hospital, it may help in the 
identification of species. If it is a harmless species, the patient can 
be reassured and discharged from the hospital. 
f. Any traditional medicine used for snake bite should be asked 
since they can cause problems and produce symptoms that      
confuse the diagnosis. 
2. The patient should be reassured since 70% of all snakebites are 
from non-venomous species . 
3. The limb should be immobilised using bandage or cloth to hold 
the splint without blocking the blood supply . 
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4. Tight clothing, shoes, watches, rings should be removed since 
they can increase the swelling due to tourniquet effect . 
5. Traditional first aid measures should be discarded as they have no 
role and may produce more harm than good . 
6. The bite wound should not be interfered by incision, rubbing, 
suction, cautery, applying herbs, chemicals since it may             
introduce infections and may increase the chances of venom     
absorption. 
7. ASV should not be injected locally . 
8. Tourniquet should be avoided as it may cause gangrene . 
The first aid recommended for snake bite can be called “Do it R.I.G.H.T” 
which is the mnemonic. 
It consists of the following : 
R = Reassure the patient. 70% snake bites are non venomous and only 
50% of bites by venomous species envenomate the patient. 
I =  Immobilise the limb in the same way for fractured limb. 
GH = Get to Hospital immediately. Traditional remedies have no proven 
benefit in treating snakebite. 
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T    = Tell the doctor about any systemic symptoms such as ptosis that 
manifest on the way to hospital. 
ASSESSMENT : 
Time elapsed since the snake bite should be determined . 
Brief medical history (presence of any systemic diseases, history of 
allergy, use of medication) should be obtained . 
PHYSICAL EXAMINATION : 
Careful examination of the bitten site and signs of local              
envenomation should be done. Patient should be monitored closely . 
The following parameters should be monitored carefully:  
1. Pulse rate,  
2. respiratory  rate, 
3. blood pressure,  
4. oxygen saturation  
5. 20 minutes Whole Blood Clotting Time ( 20 WBCT )  every hour 
for first 3 hours and every 4 hours  for next 24 hours. 
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6. Examination of distal pulses is vital in the presence of gross swell-
ing. Pain on passive movement, pallor, pulseless limb,  
hypoesthesia should lead to the diagnosis of compartment  
syndrome. The diagnosis of compartment syndrome should be 
made if the compartment pressure measured by inserting a 16 G 
IV cannula and connecting it to manometer reads above 40 cm 
water. 
EXAMINATION OF PREGNANT WOMEN : 
Uterine contractions and foetal heart rate should be                   
monitored. Lactating women should be encouraged to continue breast 
feeding. 
EARLY CLUES OF SEVERE ENVENOMING : 
a) Rapid extension of local swelling from the bitten site. 
b) Early tender enlarged lymph nodes indicates spread of venom in 
lymphatics. 
c) Signs of neurological impairment like ptosis, respiratory distress, 
muscle weakness. 
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d) bleeding manifestations like bleeding from gums, bite site,     
haematuria, hemoptysis, epistaxis, ecchymoses. 
e) Dark brown urine. 
f) Snake identified as a very venomous one. e.g Cobra, Russell’s 
Viper. 
LATE-ONSET ENVENOMING : 
The patient should be kept under close observation for at least 24 
hours. Bites from species like Viper  may take longer time for the    
symptoms to manifest. Juvenile snakes, 8-10 inches long, tend to bite on 
the foot which is a hard tissue area and hence the sings of envenomation 
can take much longer time to appear. 
LAB INVESTIGATIONS : 
 20 MINUTE WHOLE BLOOD CLOTTING TIME (20 WBCT): 
1. It is a simple bedside test . 
2. 2ml of fresh venous blood should be placed in a small glass test 
tube and should be left undisturbed for 20 minutes . 
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3. The test tube should be gently tilted to check if the blood is still 
liquid .If the blood is not clotted , then the patient has           
hypofibrinogenaemia as a result of  venom-induced consumption 
coagulopathy. 
4. If the blood clot is formed but patient has signs and symptoms of 
neurotoxic envenomation, patient should be treated for neurotoxic 
envenomation . 
5. If there is any doubt, the test should be repeated with  a control 
from healthy person . 
6. If the test tube is not made of ordinary glass or if it is cleaned 
with detergent, its wall will not stimulate clotting of blood sample 
and the test may be invalid . 
7. If the blood is clotted, the test should be repeated every 1 hour for 
next 3 hours and then 6 hourly for 24 hours.  
8. If the blood is not clotted, the test should be repeated after 6 
hours of loading dose of  ASV. 
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Figure 16 Minute whole blood clotting test (20 WBCT) 
 
 
OTHER LAB TESTS: 
1. Complete Blood Count 
2. Prothombin time 
3. Liver function test 
4. Renal Function test 
5. Blood sugar 
6. ECG 
7. Abdominal ultrasound  
 
 
47 
 
INTERPRETATION OF THE TESTS :     
HEMOGRAM: Hemogram may show transient increase in hemoglobin 
level due to hemoconcentration  which is due to increased capillary leak 
or may show anemia due to hemolysis especially in viper bites.  
Neutrophilic leucocytosis may be due to systemic venom absorption. 
Thrombocytopenia may be a feature of viper envenomation. 
PERIPHERAL SMEAR: Fragmented red cells (“helmet cell”,       
schistocytes ) are seen if there is microangiopathic haemolysis. 
SERUM CREATININE: It is necessary to rule out acute kidney injury. 
SERUM CREATININE PHOSPHOKINASE (CPK): Elevated levels of 
CPK suggests muscle damage. 
URINE EXAMINATION : Check for Proteinuria, RBC,                   
Haemoglobinuria, Myoglobinuria. The colour of the urine (pink, red, 
brown) should be noted and should be tested for blood, haemoglobin, 
myoglobin. 
ELECTROCARDIOGRAM (ECG): ECG changes like bradycardia,   
atrioventricular block with ST-T changes may be seen . 
 
 
48 
 
ASV : 
1. Antisnake venom is the only specific antidote for snake bite 
which should be given as soon as it is indicated. 
2. There are no absolute contraindication to ASV. 
3. ASV may reverse systemic envenomation abnormality. 
4. In India, polyvalent ASV, i.e. effective against all four common 
species (Russell’s viper, common cobra, common Krait and       
saw -scaled viper ) is available  
5. ASV is produced both in liquid and lyophilized forms. Liquid 
ASV should be stored in a reliable cold chain and has shelf life of 
2 years. Lyophilised ASV, in powder form, has shelf life of 5 
years and can be stored in cool place. 
6. ASV is a sterile preparation containing equine immunoglobulin 
fragments F(ab’)2  prepared from plasma of a horse immunised 
with the venom of one or more snake species. 
7. ASV can be either Monovalent or Polyvalent. Monovalent         
antivenom neutralizes the venom of only one snake species 
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whereas Polyvalent antivenom neutralizes the venom of several 
different snake species. 
8. Each ml has capacity of specifically neutralizing the venom of the 
following species of snakes: 
a. 0.60mg of dried Indian Cobra  (Naja naja) venom. 
b. 0.45mg of dried Common Krait (Bungarus Caeruleus)    
venom . 
c. 0.60mg of dried Russell’s Viper (Daboia russelii) venom. 
d. 0.45mg of dried Saw-scaled viper (Echis carinatus) venom . 
9. The antitoxic equine Immunoglobulin and their derivatives are 
obtained from the serum of healthy equines immunized against 
venoms of the above species of snakes . 
10. ASV should be given only by the IV route, and should be given 
slowly. The rate of infusion can be increased gradually in the   
absence of a reaction.  
11. Epinephrine should always be kept ready before ASV is          
administered. ASV should never be given by IM route due to 
poor bioavailability  
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DOSE OF ASV FOR NEUROPARALYTIC SNAKEBITE: 
10 vials of ASV stat as infusion over 30 minutes should be given. Second 
dose of 10 vials should be given after 1 hour if there is no improvement 
within 1 hour. 
DOSE OF ASV FOR VASCULOTOXIC SNAKEBITE: 
    Two regimens are followed for vasculotoxic snake bite. 
Low Dose infusion therapy : 
10 vials for Russel’s Viper; 6 vials for saw scaled viper as a stat  
infusion over 30 minutes followed by 2 vials for every 6 hours as an     
infusion in 100 ml of normal saline, till the clotting time normalises or for 
3 days whichever is earlier. 
High dose intermittent bolus therapy: 
10 vials ASV as a stat over 30 minutes as an  infusion followed by 
6 vials  every 6 hourly as a bolus till clotting time normalises . 
The range of venom injected is from 5mg to 147mg. The total     
required dose range of ASV is between  10 and 30 vials since each vial 
neutralizes 6mg of Russell’s viper venom. 
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ASV REACTION: 
No ASV test dose is needed  
Rarely patients may develop anaphylaxis characterized by          
hypotension, bronchospasm, and angioedema. 
EARLY ANAPHYLACTIC REACTION occurs within 10 to 180 min of 
start ASV infusion. Itching, urticaria, dry cough, nausea, vomiting,      
abdominal colic, tacchycardia may develop. 
PYROGENIC REACTIONS develop 1 to 2 hours after treatment  which 
include chills and rigors, fever and hypotension.  
Any new sign or symptom after starting the ASV should be considered as 
a reaction to ASV. 
LATE REACTIONS develop 1 to 12 days after treatment. Clinical      
features are fever, vomiting, diarrhoea, urtricaria, arthralgia, myalgia,   
nephritis, rarely encephalopathy. 
TREATMENT OF EARLY ASV REACTION: 
Adrenaline should be given intramuscularly in an initial dose of 
0.5mg for adults, 0.01mg/kg body weight for children; ideally into upper 
lateral thigh. Adrenaline has been proved safe in pregnant women but   
anaphylaxis can induce abortion. Since life threatening anaphylaxis may 
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evolve very rapidly, adrenaline should be given at the very first sign of a 
reaction. The dose must be repeated every 5 to 10 minutes if the reaction 
persists or become worse. 
Patient can also be given an antihistamine like chlorpheniramine 
maleate (10mg for adults and 2mg/kg for children) through intrvenous 
route over a few minutes. 
Hydrocortisone (100mg in adults, 2mg/kg body weight in children) 
can be given through intravenous route. But it does not reduce the risk of 
recurrence since it is unlikely to act for several hours. 
ANAPHYLAXIS UNRESPONSIVE TO INTRAMUSCULAR 
ADRENALINE 
Some patients who do not respond to the repeated doses of          
intramuscular adrenaline and who remain shocked and hypotensive 
should be laid supine with their legs elevated and should be given         
intravenous volume replacement with 0.9% saline, usually 1-2 litres    
rapidly . 
Adrenaline should be given as intravenous infusion [adult dose 
1mg in 250ml of 5% dextrose or 0.9% saline in 4 microgram /ml concen-
tration; infused at 1-4 microgram/minute (15 to 60 drops/min). The        
infusion rate can be increased upto 10 microgram/min . 
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If the patient remains hypotensive, a vasopressor agent like        
dopamine [dose 400mg in 500ml 5%dextrose or 0.9% saline] should be 
infused at the rate of 2-5 microgram /kg/min. 
RECURRENT SYSTEMIC ENVENOMATION: 
Recurrence of systemic envenomation has been observed in 24 to 
48 hours of initial recovery which is due to continuing absorption of   
venom from the bitten site that occurs after the improvement in blood 
supply following correction of shock and hypovolemia and disappearance 
of ASV from circulation. It is rare in India due to the prolonged half-life 
of polyvalent ASV. It is also due to redistribution of venom from tissue 
into vascular space as a result of antivenin therapy. So it is ideal to       
observe the patient for 48 hours after the recovery. 
TREATMENT OF OLIGURIA AND ACUTE KIDNEY INJURY 
DETECTION OF ACUTE KIDNEY INJURY 
1. If urine output  is  <0.5ml/kg/hr for more than 6 hours. 
2. If there is an increase in serum creatinine concentration [serum 
creatinine >0.3 mg/dl or increasing by (1.5 to 2 times ) from the 
baseline value. 
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3. If there is a clinical “uraemia syndrome” defined by nausea,  
vomiting, acidotic breathing, hiccups, drowsiness, flapping  
tremor, muscle twitching, pericardial friction rub and signs of 
volume overload. 
OLIGURIC PHASE OF RENAL FAILURE 
Not all patients with acute renal failure become oliguric. (defined 
as urine output of less than 400ml/day or less than 30ml/hour.            
Conservative management will avoid the need of renal replacement   
therapy . 
If the patient has intravascular volume depletion indicated by    
postural hypotension, the following measures should be followed. 
Intravenous access should be established. 
Cautious fluid challenge should be given. Adult patient should be 
given 250-500ml of isotonic saline over 1 hour and the patient must be 
closely observed for the development of pulmonary edema. The fluid 
challenge must be stopped if there are signs of pulmonary edema. 
A frusemide stress test must be performed if there is no improve-
ment in urine output. Urethral catheter must be inserted before the test 
.Once the patient has been given adequate fluid replacement, 1 to 
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1.5mg/kg of frusemide should be injected slowly through intravenous 
route (4-5mg/minute) and the urine output should be monitored for 2 
hours. If the urine output is less than 200ml in an hour, it denotes the  
progression to acute kidney injury. Despite these challenges, if there is no 
improvement in urine output, diuretics should be stopped  and the fluid 
intake should be restricted to a total of the previous day’s output plus       
“insensible losses” (500-1000ml/day). The patient should be promptly   
referred to a renal unit and the bland diet should be advised which is high 
in calories (1800/day), normal in protein (0.8-1g/day), low in potassium 
(avoid fruits, juices). The patient should be treated with non-nephrotoxic 
antibiotics. 
Patients with Acute kidney injury should be monitored daily for 
urea, creatinine, electrolytes, pH, bicarbonate, calcium and phosphate 
.ECG should be taken for the evidence of hyperkalemia.  
INDICATION FOR DIALYSIS 
1. Patients who develop features of clinical uraemia like               
encephalopathy, pericarditis. 
2. Patients with volume overload and not responding to diuretics. 
3. Hyperkalemia; plasma potassium > 7mmol/l. 
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4. Symptomatic acidosis. 
5. Creatinine  > 4mg/dl; urea > 130 mg/dl  
COMPARTMENTAL SYNDROME 
An immobile, tensely swollen, cold and pulseless snake bitten limb 
suggests the possibility of increased intracompartmental                     
pressure. Swelling of the envenomed muscle within tight fascial        
compartments like the digital pulp space or tibial compartment could    
increase the tissue pressure above the venous pressure resulting in        
ischaemia. Detection of arterial pulses by palpation or doppler does not 
necessarily rule out intracompartmental ischaemia. Measuring the         
intracompartmental pressure directly by a cannula introduced into the 
compartment and connecting to a pressure manometer is the most reliable 
test. Intracompartmental pressure exceeding 40 mmHg carries the risk of 
ischaemic necrosis. As a rule, fasciotomy should not be carried out   
without correcting the haemostatic abnormalities, otherwise the patient 
may bleed to death.Early and prompt treatment with antivenom is the best 
way to prevent the irreversible muscle damage. 
 
 
57 
 
Clinical features of a compartmental syndrome: 
1. severe pain  which is disproportionate . 
2. Intracompartmental muscle weakness. 
3. Intracompartmental muscular pain on passive stretching. 
4. Hypoesthesia of  areas of skin which are  supplied by nerves  
running through the compartment. 
5. The compartment on palpation, produces obvious tenderness. 
 
Criteria for fasciotomy in snake bitten limb : 
1. Haemostatic abnormalities have been corrected with antivenom 
and clotting factors. 
2. Clinical evidence of intracompartmental syndrome. 
3. Intracompartmental pressure > 40 mmHg. 
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Fig. 17 Measurement of compartmental pressure 
 
 
 
59 
 
MATERIALS AND METHODS 
STUDY DESIGN:  
Observational, descriptive study of longitudinal design. 
SOURCE OF SUBJECTS: 
Patient presenting to the Department of General medicine and admitted in 
Coimbatore Medical College Hospital with the history of snake bite were 
included in the study. 
SOURCE OF DATA:  
Data consists of primary data collected by the principal investigator      
directly from the snake bite cases admitted to The Department of General 
Medicine, CMCH. 
DURATION OF STUDY: JULY 2016 to JUNE 2017 
SAMPLE SIZE: 100 
INCLUSION CRITERIA: 
All the adult cases of snake bite admitted to The Department of General 
Medicine, CMCH with signs of envenomation. 
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EXCLUSION CRITERIA: 
1. Children < 13 years. 
2. Pregnant women. 
3. Those who received ASV, prior to the admission in CMCH. 
4. Snake bite cases without features of envenomation and those who 
did not require ASV. 
5. Doubtful cases of snake bite with no definitive history. 
6. Those with chronic diseases like CAD, CKD, Diabetes. 
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METHODOLOGY 
The study was undertaken on patients admitted to CMCH with    
history of snake bite during the study period which is from JULY 2016 to 
JUNE 2017. 
A total number of 100 patients were included in the study after   
fulfilling the inclusion and exclusion criteria. After getting the informed 
consent from the patient to participate in the study, history and physical 
examination details were collected. Detailed history includes the time 
since snake bite, bitten site, species of snake bite, symptoms at       
presentation :- level of consciousness, pain at the bitten site, cellulitis, 
vomiting, abdominal pain, ptosis, respiratory failure, oliguria, bleeding 
manifestations. Thorough physical examination of CVS, RS, Abdomen 
and CNS was done. Investigations like WBCT, CBC, RFT, LFT,         
Coagulation profile, urine analysis were done. ASV was given as per the 
existing institutional protocol. “BITE TO NEEDLE TIME” is noted. The 
total number of ASV vials given was noted. The patient were closely 
monitored for the development of complications until the time of         
discharge.  
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Complications were defined as: 
1. ACUTE KIDNEY INJURY : Serum creatinine > 1.5 mg/dl or   
oliguria < 400ml/day . 
2. Disseminated intravascular coagulation. 
3. Compartmental syndrome, gangrene, cellulitis that required    
debridement. 
4. Shock, sepsis . 
5. Neurological paralysis requiring ventilatory support. 
Any correlation between timing of ASV administration and the following 
parameters were studied. 
a) Development of complications. 
b) Duration of stay. 
c) Total requirement of ASV. 
d) Final outcome. 
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STATISTICAL ANALYSIS 
 
All the data were entered in a data collection sheet in an Excel format and 
analysed using SPSS Software. Numerical values were reported using 
mean and standard deviation or median. Categorical values are reported 
using numbers and percentages. Probability value (p) value less than 0.05 
was considered a statistically significant. 
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RESULTS 
 
TABLE 5.1 AGE DISTRIBUTION 
AGE (IN YEARS) NO OF PATIENTS PERCENTAGE 
< 20 9 9% 
21-30 19 19% 
21-40 26 26% 
41-50 20 20% 
51-60 14 14% 
> 60 12 12% 
 
CHART 5.1 AGE DISTRIBUTION 
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TABLE 5.2 SEX DISTRIBUTION 
SEX NO OF PATIENTS PERCENTAGE 
MALE 68 68% 
FEMALE 32 32% 
 
 
CHART 5.2 SEX DISTRIBUTION 
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TABLE 5.3 SNAKE SPECIES 
SNAKE SPECIES NO OF PATIENTS PERCENTAGE 
KRAIT 40 40% 
COBRA 12 12% 
VIPER 30 30% 
NOT IDENTIFIED 18 18% 
 
 
CHART 5.3 SNAKE SPECIES 
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TABLE 5.4 BITE TO NEEDLE TIME 
BITE TO NEEDLE TIME NO OF PATIENTS PERCENTAGE 
< 6 HRS 36 36% 
6 -12 HRS 30 30% 
12-24 HRS 22 22% 
> 24 HRS 12 12% 
 
 
CHART 5.4 BITE TO NEEDLE TIME 
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TABLE 5.5 BITE SITE 
BITE SITE NO OF PATIENTS PERCENTAGE 
UPPER LIMB 37 37% 
LOWER LIMB 63 63% 
 
 
CHART 5.5 BITE SITE 
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TABLE 5.6 TOTAL ASV 
TOTAL ASV NO OF PATIENTS PERCENTAGE 
10 VIALS 4 4% 
20 VIALS 35 35% 
30 VIALS 61 61% 
 
 
CHART 5.6 TOTAL ASV 
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TABLE 5.7 WHOLE BLOOD CT 
WHOLE BLOOD CT NO OF PATIENTS PERCENTAGE 
MORE THAN 20 MIN 84 84% 
LESS THAN 20 MIN 16 16% 
 
 
CHART 5.7 WHOLE BLOOD CT 
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TABLE 5.8 HOSPITAL STAY 
HOSPITAL STAY NO OF PATIENTS PERCENTAGE 
< 5 DAYS 28 28% 
5-10 DAYS 51 51% 
> 15 DAYS 21 21% 
 
 
CHART 5.8 HOSPITAL STAY 
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TABLE 5.9 CASES WITH  CELLULITIS 
CELLULITIS NO OF PATIENTS PERCENTAGE 
PRESENT 50 50% 
ABSENT 50 50% 
 
 
CHARTS 5.9 CASES WITH CELLULITIS 
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TABLE 5.10 CASES WITH AKI 
ACUTE KIDNEY INJURY NO OF PATIENTS PERCENTAGE 
PRESENT 34 34% 
ABSENT 66 66% 
 
 
CHART 5.10 CASES WITH AKI 
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TABLE 5.11 CASES WITH DIC 
DIC NO OF PATIENTS PERCENTAGE 
PRESENT 10 10% 
ABSENT 87 87% 
 
 
CHART 5.11 CASES WITH DIC 
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TABLE 5.12  CASES WITH SEPTIC SHOCK 
SEPTIC SHOCK NO OF PATIENTS PERCENTAGE 
PRESENT 12 50% 
ABSENT 88 50% 
 
 
CHART 5.12 CASES WITH SEPTIC SHOCK 
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TABLE 5.13 CASES WITH RESPIRATORY FAILURE 
RESPIRATORY FAILURE NO OF PATIENTS PERCENTAGE 
PRESENT 10 10% 
ABSENT 90 90% 
 
 
CHART 5.13 CASES WITH RESPIRATORY FAILURE 
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TABLE 5.14 FINAL OUTCOME 
FINAL OUTCOME NO OF PATIENTS PERCENTAGE 
DEATH 9 9% 
ALIVE 91 91% 
 
 
CHART 5.14 FINAL OUTCOME 
 
 
 
78 
 
TABLE 5.15 CORRELATION BETWEEN BITE TO NEEDLE 
TIME AND  ASV 
BITE TO NEEDLE TIME 
TOTAL ASV 
10 VIAL 20 VIAL 30 VIAL 
LESS THAN 6 HR 4 29 3 
6-12 HR 0 4 26 
12-24 HR 0 2 20 
MORE THAN 24 HR 0 0 12 
P VALUE - 0.001 
SIGNIFICANT 
KRUSKAL WALLIS TEST 
 
CHART 5.15 CORRELATION BETWEEN BITE TO 
NEEDLE TIME AND 
ASV
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TABLE 5.16 CORRELATION BETWEEN BITE TO NEEDLE 
TIME AND STAY PERIOD 
BITE TO NEEDLE TIME 
STAY PERIOD 
< 5 DAYS 5-10 DAYS > 10 DAYS 
LESS THAN 6 HR 27 9 0 
6-12 HR 1 20 9 
12-24 HR 0 15 7 
MORE THAN 24 HR 0 7 5 
P VALUE - 0.001 
SIGNIFICANT 
KRUSKAL WALLIS TEST 
 
 
CHART 5.16 CORRELATION BETWEEN BITE TO NEEDLE 
TIME VS STAY PERIOD 
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TABLE 5.17 CORRELATION BITE TO NEEDLE TIME  
VS CELLULITIS 
BITE TO NEEDLE TIME 
CELLULITIS 
PRESENT ABSENT 
LESS THAN 6 HR 1 35 
6-12 HR 17 13 
12-24 HR 21 1 
MORE THAN 24 HR 11 1 
P VALUE - 0.001 
SIGNIFICANT 
KRUSKAL WALLIS TEST 
 
 
CHART 5.17 CORRELATION BETWEEN BITE TO NEEDLE 
TIME VS CELLULITIS 
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TABLE 5.18 CORRELATION BETWEEN BITE TO NEEDLE 
TIME VS AKI 
BITE TO NEEDLE TIME 
ACUTE KIDNEY INJURY 
PRESENT ABSENT 
LESS THAN 6 HR 4 32 
6-12 HR 8 22 
12-24 HR 10 12 
MORE THAN 24 HR 2 0 
P VALUE - 0.001 
SIGNIFICANT 
KRUSKAL WALLIS TEST 
 
 
CHART 5.18 CORRELATION BETWEEN BITE TO NEEDLE 
TIME VS AKI 
 
 
 
 
82 
 
TABLE 5.19 CORRELATION BETWEEN BITE TO NEEDLE 
TIME VS DIC 
BITE TO NEEDLE TIME 
DIC 
PRESENT ABSENT 
LESS THAN 6 HR 0 36 
6-12 HR 0 30 
12-24 HR 4 18 
MORE THAN 24 HR 9 3 
P VALUE - 0.001 
SIGNIFICANT 
KRUSKAL WALLIS TEST 
 
 
CHART 5.19 CORRELATION BETWEEN BITE TO  
NEEDLE TIME VS DIC 
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TABLE 5.20 CORRELATION BETWEEN BITE TO NEEDLE 
TIME VS SEPTIC SHOCK 
BITE TO NEEDLE TIME 
SEPTIC SHOCK 
PRESENT ABSENT 
LESS THAN 6 HR 0 36 
6-12 HR 1 29 
12-24 HR 4 18 
MORE THAN 24 HR 7 5 
P VALUE - 0.001 
SIGNIFICANT 
KRUSKAL WALLIS TEST 
 
 
CHART 5.20 CORRELATION BETWEEN BITE TO NEEDLE 
TIME VS SEPTIC SHOCK 
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TABLE 5.21 CORRELATION BETWEEN BITE TO NEEDLE 
TIME VS RS FAILURE 
BITE TO NEEDLE TIME 
RESPIRATORY FAILURE 
PRESENT ABSENT 
LESS THAN 6 HR 0 36 
6-12 HR 6 24 
12-24 HR 3 19 
MORE THAN 24 HR 1 11 
P VALUE - 0.053 
NON SIGNIFICANT 
KRUSKAL WALLIS TEST 
 
 
CHART 5.21 CORRELATION BETWEEN BITE TO NEEDLE 
TIME VS RS FAILURE 
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TABLE 5.22 CORRELATION BETWEEN BITE TO NEEDLE 
TIME VS FINAL OUTCOME 
BITE TO NEEDLE TIME 
FINAL OUTCOME 
DEATH ALIVE 
LESS THAN 6 HR 0 36 
6-12 HR 0 30 
12-24 HR 1 21 
MORE THAN 24 HR 8 4 
P VALUE - 0.001 
SIGNIFICANT 
KRUSKAL WALLIS TEST 
 
 
CHART 5.22 CORRELATION BETWEEN BITE TO NEEDLE 
TIME VS FINAL OUTCOME 
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TABLE 5.23 CORRELATION BETWEEN SEX AND  
FINAL OUTCOME 
SEX 
FINAL OUTCOME 
DEAD ALIVE 
MALE 5 63 
FEMALE 4 28 
P VALUE - 0.401 
NON SIGNIFICANT 
CHI SQUARE TEST 
 
 
CHART 5.23 CORRELATION BETWEEN SEX VS  
FINAL OUTCOME 
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TABLE 5.24 CORRELATION BETWEEN SNAKE SPECIES VS 
FINAL OUTCOME 
SNAKE SPECIES 
FINAL OUTCOME 
DEAD ALIVE 
KRAIT 4 36 
COBRA 1 11 
VIPER 3 27 
NOT IDENTIFIED 1 17 
P VALUE - 0.950 
NON SIGNIFICANT 
KRUSKAL WALLIS TEST 
 
 
CHART 5.24 CORRELATION BETWEEN SNAKE  
SPECIES VS FINAL OUTCOME 
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TABLE 5.25 CORRELATION BETWEEN BITE SITE VS  
FINAL OUTCOME 
 
 
CHART 5.25 CORRELATION BETWEEN BITE SITE VS FINAL 
OUTCOME 
 
 
 
 
BITE SITE 
FINAL OUTCOME 
DEAD ALIVE 
UPPER LIMB 4 33 
LOWER LIMB 5 58 
P VALUE - 0.628 
NON SIGNIFICANT 
CHI SQUARE TEST 
 
 
89 
 
TABLE 5.26 CORRELATION BETWEEN STAY PERIOD AND 
FINAL OUTCOME 
 
 
CHART 5.26 CORRELATION BETWEEN STAY PERIOD AND 
FINAL OUTCOME 
 
 
 
 
STAY PERIOD 
FINAL OUTCOME 
DEAD ALIVE 
< 5 DAYS 0 28 
5-10 DAYS 5 46 
> 10 DAYS 4 17 
P VALUE - 0.025 
SIGNIFICANT 
KRUSKAL WALLIS TEST 
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TABLE 5.27 CORRELATION BETWEEN CELLULITIS AND  
FINAL OUTCOME 
 
 
CHART 5.27 CORRELATION BETWEEN CELLULITIS  
AND FINAL OUTCOME 
 
 
 FINAL OUTCOME 
CELLULITIS DEAD ALIVE 
PRESENT 8 42 
ABSENT 1 49 
P VALUE - 0.014 
SIGNIFICANT 
CHI SQUARE TEST 
 
 
91 
 
TABLE 5.28 CORRELATION BETWEEN DIC AND  
FINAL OUTCOME 
 
 
CHART 5.28 CORRELATION BETWEEN DIC AND 
FINAL OUTCOME 
 
DIC 
FINAL OUTCOME 
DEAD ALIVE 
PRESENT 7 3 
ABSENT 2 86 
P VALUE - 0.001 
SIGNIFICANT 
CHI SQUARE TEST 
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TABLE 5.29 CORRELATION BETWEEN AKI AND  
FINAL OUTCOME 
ACUTE KIDNEY INJURY 
FINAL OUTCOME 
DEAD ALIVE 
PRESENT 9 25 
ABSENT 0 66 
P VALUE - 0.001 
SIGNIFICANT 
CHI SQUARE TEST 
 
 
CHART 5.29 CORRELATION BETWEEN AKI AND  
FINAL OUTCOME 
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TABLE 5.30 CORRELATION BETWEEN RESPIRATORY FAIL-
URE AND FINAL OUTCOME 
RESPIRATORY FAILURE 
FINAL OUTCOME 
DEAD ALIVE 
PRESENT 8 2 
ABSENT 1 87 
P VALUE - 0.002 
SIGNIFICANT 
CHI SQUARE TEST 
 
 
CHART 5.30 CORRELATION BETWEEN RESPIRATORY FAIL-
URE AND FINAL OUTCOME 
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TABLE 5.31 CORRELATION BETWEEN SEPTIC SHOCK AND 
FINAL OUTCOME 
 
 
CHART 5.31 CORRELATION BETWEEN SEPTIC SHOCK AND 
FINAL OUTCOME 
 
 
 
 
 
SEPTIC SHOCK 
FINAL OUTCOME 
DEAD ALIVE 
PRESENT 6 6 
ABSENT 3 85 
P VALUE - 0.001 
SIGNIFICANT 
CHI SQUARE TEST 
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DISCUSSION 
The present study comprised of 100 cases who presented with    
history of snake bite and with signs of envenomation during the study   
period. A detailed history and meticulous clinical examination and        
investigations were carried out from the day of admission till discharge. 
Data records include the patient’s  characteristics like  signs and       
symptoms, complications, dose of ASV, duration of hospital stay, final 
outcome. The data was analyzed for predicting survival using statistical 
analysis. 
            In the present study, 68% of the patients were males as compared 
to 32% of females. This male preponderance was similar to the findings 
of other studies which may be attributed to their lifestyles and               
occupational exposures like farmers or herdsman. In the present study, 
most of snake bites were in the age group of 31 to 40 years comprising of 
26% followed by 41 to 50 years comprising of 20%. Patients less than 20 
years contributed least of 9%. 
              Krait bites were higher with 40% followed by viper with       
30%, cobra contributed 12%. In18% of bites, the species was not        
identified. 36% of patients received ASV within 6 hours of snake bite; 
30% of patients within 6 to 12 hours, 22 % of patients in 12 to 24 hours 
,about 12% of patient received ASV only after 24 hours which may be 
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due to delayed referral and because of a trial of native treatment and     
delayed onset of complications. 
         63% of patients had bite in lower limb and 37% of patient had bites 
in upper limb. Two patients had bite in unusual areas like hip and chin. 
4 patients received 10 vials of ASV. 35 patients received 20 vials 
of ASV. 61 patients received 30 vials of ASV. 
Cellulitis was present in 50 patients. Acute kidney injury was    
present in 34% of patient. 10% of patients developed DIC; 12%           
developed septic shock; 10% developed respiratory failure. As bite to bite 
time is increased, the complications like DIC, AKI, septic shock, cellulitis 
also increased. 
        In less than 6 hours category; only 1 patient developed cellulitis 
whereas in 6 - 12 hours category, 17 patients developed cellulitis and 21 
patients in 12 - 24 hours category. 
        4 patients developed AKI in less than 6 hours category while 8      
patients in 6 -12 hours and 10 patients in 12 - 24 hours. 
       DIC was seen only in the categories of 12 - 24 hours (4 patients) and 
> 24 hours (9 patients). 
Septic shock was maximum in the category of > 24 hours (7 patients) and 
is absent in less than 6 hours. 
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Respiratory failure is maximum in 6 - 12 hours category (6 patients) and 
absent in less than 6 hours. 
        As the bite to needle time increased, the total number of ASV vials 
required also increased. 4 patients received 10 vials; 29 patients received 
20 vials and only 3 patients received 30 vials in less than 6 hours category 
.But in the category of more than 24 hours all the patients (12) received 
30 vials of ASV. In 12 to 24 hours category; 2 patients received 20 vials, 
20 patients received 30 vials. 
The stay period in hospital also increased with the bite to needle 
time. The stay period in most of the patients in less than 6 hours was less 
than 5 days and no patient stayed more than 10 days. But in other        
categories, most of the patients stayed more than 5 days . 
The total number of death was 9.  male - 5 and female - 4. No 
deaths in less than 6 hours and 6 - 12 hours ; 1 death in 12 - 24 hours and 
8 deaths in > 24 hours. 
Krait accounted for 4 deaths;  viper for 3 deaths; cobra for 1 death; 
For 1 death - the species in unidentified. 
Among the 9 death cases; 8 had cellulitis; 7 had DIC; 9 had AKI; 8 
had respiratory failure; 6 had septic shock. 
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SUMMARY 
 
1. 100 patients with snake bite envenomation were included in the 
study which was done between JULY 2016 to JUNE 2017 at      
Coimbatore Medical College Hospital. 
2. Commonest age group involved is 31 - 40 years. 
3. Males were affected the most common than the women. 
4. Majority of snake bites were due to Krait and Cobra bites being the 
least. 
5. Most common complication was cellulitis and the least common 
were DIC and respiratory failure. 
6. Complications were higher in the patients who received ASV very 
late. i.e more than 6 hours from the bite. 
7. Duration of hospital stay was also more in those who received 
ASV very late. 
8. The total amount of ASV vials required was higher among those 
with “BITE TO NEEDLE TIME” of more than 6 hours. 
9. Most of the deaths were due to Krait and all the deaths were in                
the  patients who received ASV after 12 - 24 hours.    
10. Overall the patients who received ASV within 6 hours of snake bite                 
had better prognosis than those who received ASV after 6 hours. 
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CONCLUSION 
 
This study has revealed that “THE BITE TO NEEDLE TIME” is a 
better predictor of survival in the snake bite envenomation. The earlier 
the administration of ASV, lesser the complications and duration of stay 
and better the prognosis. The incidence of complications was directly 
proportional to the duration of venom in the blood prior to its              
neutralisation by ASV. Based on the findings of the present study, it is 
suggested that the early institution of ASV is beneficial to prevent the 
complications like AKI, DIC and respiratory paralysis. The delay in ASV 
administration could increase the incidence of AKI, DIC, respiratory    
paralysis and   morbidity as observed from the present study. Hence it is 
important to make the availability of ASV universal in the areas where 
the incidence of snake bite is high and to adequately train the health care 
providers about the appropriate management of snake bite patients in    
order to decrease the morbidity and mortality. 
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PROFORMA 
 
Name :                                                    Age :                 Sex :                     
IP No : 
 
Duration of stay: 
 
Site of Bite :                                          Species of Snake : 
 
Clinical symptoms : 
 
Past History : DM/HT/CAD etc. 
 
Clinical Examination : 
 
Pulse                       BP                 TEMP             RESP RATE                
SPO2  
 
CVS : 
 
   RS :   
 
ABD : 
CNS : 
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COMPLICATIONS : 
1. CELLULITIS Yes / No 
2. A.K.I Yes / No 
3. D.I.C Yes / No 
4. RESPIRATORY FAILURE Yes / No 
5. SEPTIC SHOCK Yes / No 
 
BITE TO NEEDLE TIME : 
TOTAL ASV GIVEN : 
LAB INVESTIGATIONS : 
1. Complete Blood Count 
2. Renal Function Tests 
3. Liver Function Tests 
4. Urine routine 
5. Coagulation Profile 
6. USG Abdomen 
7. Peripheral Smear 
8. Chest Radiograph 
9. ECG 
10. WBCT :  
 
OUTCOME: 
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CONSENT FORM 
 
 I  Mr/Mrs ______________________________ hereby volunteer to   
participate in the study" TIME INTERVAL BETWEEN SNAKE BITE 
AND ANTI-SNAKE VENOM (ASV) ADMINISTRATION AS A 
PROGNOSTIC INDICATOR IN SNAKE BITE                              
ENVENOMATION". I was completely  explained  about  the  nature  of  
the study  by  the  doctor,  knowing  which I fully give my  consent to       
participate  in  this  study. I also give consent to take clinical photographs 
for the purpose of this study. 
 
 
Date:  
Place:                                               Signature  of  the  Patient/Guardian 
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xg;Gjy; gbtk; 
 
 
ngaH    :                              taJ  : 
ghypdk;  :  
Kfthp   : 
 
muR Nfhit kUj;Jtf; fy;Y}hpapy; nghJ kUj;Jtj;  
Jiwapy; (gl;l Nkw;gbg;G gapYk; khztd; kU. nr. jkpH;f;Fkud; 
mth;fs; Nkw;nfhsSk; “ghk;g[ fo kw;Wk; ghk;g[ fo tp# Kwpt[ kUe;J 
bfhLg;gjw;F cs;s fhy ,ilbtspa[k; kw;Wk; neha; Kd;fzpg;g[ 
fhl;oa[k;” Ma;tpd; nra;Kiw njhlh;ghd midj;J tpguq;fisAk; 
Nfl;L  vdJ re;Njfq;fisj; njspTgLj;jpf; nfhz;Nld;. 
 
     ehd; ,e;j Ma;tpy; vd;id / vd; Foe;ijia ghpNrhjid 
nra;a KO kdJlDk; Rarpe;NidAlDk; rk;kjpf;fpNwd;. vd;/ vd; 
Foe;ijapd; Neha; gw;wpa ,e;j Ma;tpy; vq;fsJ midj;J 
tpguq;fSk; ghJfhf;fg;gLJld; Neha; gFjpapd; Gifg;glk; 
kw;Wk;,jd;  KbTfs;  Ma;tpjopy;  ntspaplg;gLtjpy;      
Ml;-Nrgid ,y;iy vd;gijj; njhptpj;Jf;nfhs;fpNwd;. ve;j  
Neuj;jpYk; ,e;j Ma;tpypUe;J ehd; tpyfpf;nfhs;s vdf;F chpik 
cz;L vd;gijAk; mwpNtd;. 
 
 
,lk;   :                   Nehahsp/ Foe;ijapd; n;gw;Nwhh; 
ehs;   :                   my;yJ ghJfhtyh; ifnahg;gk;. 
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KEY TO MASTER CHART 
SEX    
Male      1 
Female  2 
 
SNAKE SPECIES 
krait  1 
cobra  2 
viper  3 
unidentified  4 
BITE SITE 
upper limb  1 
lower limb 2 
BITE TO NEEDLE TIME 
 < 6hrs  1 
6 - 12 hrs  2 
12-24 hrs 3 
>24 hrs 4 
 
TOTAL ASV VIALS 
10  VIALS 1 
20 VIALS 2   
30 VIALS  3 
WBCT 
>20 MIN 1   
< 20MIN 2 
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HOSPITAL STAY 
<5DAYS          1 
5-10DAYS       2 
>10 DAYS         3 
CELLULITIS    
YES     1 
NO  2 
AKI 
YES  1 
NO 2 
DIC 
YES 1  
NO  2 
SHOCK 
YES  1  
NO  2 
RESPIRATORY FAILURE 
YES  1  
NO  2 
DEATH 
YES  1 
NO  2 
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MASTER CHART 
S.No NAME AGE SEX SNAKE    SPECIES 
BITE 
SITE 
BITE -NEEDLE 
TIME 
TOTAL 
ASV WBCT 
STAY 
PERIOD CELLULITIS DIC AKI 
RESP 
FAILURE 
SEPTIC 
SHOCK DEATH 
1 KALIYAMMAL 65 2 1 2 3 3 1 2 1 2 2 2 2 2 
2 PRABHU 25 1 1 2 2 3 1 2 2 2 2 2 2 2 
3 VIMALA 35 2 1 1 2 2 1 2 1 2 2 2 2 2 
4 YUVARAJ 37 1 1 1 2 3 1 2 1 2 2 2 2 2 
5 PAPPAN 45 1 4 2 1 2 1 1 2 2 2 2 2 2 
6 RAMASAMY 57 1 1 2 4 3 1 2 1 1 1 2 1 1 
7 GOVARTHINI 24 2 3 1 3 3 2 2 1 2 2 2 2 2 
8 PALANISAMY 55 1 3 2 3 2 2 2 1 2 2 2 2 2 
9 MANIKAM 60 1 1 2 1 2 1 1 2 2 2 2 2 2 
10 MANIMEGALAI 42 2 4 1 3 3 1 2 1 2 1 2 2 2 
11 DEVARAJ 47 1 1 1 2 3 1 3 2 2 1 2 1 2 
12 DURAISAMY 71 1 3 1 1 2 1 1 2 2 2 2 2 2 
13 SANGEETHA 16 2 1 1 3 3 1 2 1 2 2 2 2 2 
14 NATCHAMMAL 56 2 3 1 4 3 2 2 1 2 1 2 2 1 
15 PRADEEP 35 1 1 2 1 2 1 2 2 2 2 2 2 2 
16 MAYANDI 59 1 2 1 2 3 2 3 2 2 2 1 2 2 
17 VINOTH 30 1 1 2 3 3 1 2 1 2 2 2 2 2 
18 VENKATESH 45 1 1 1 2 3 1 3 2 2 2 2 2 2 
19 SURENDAR 24 1 3 1 1 2 1 1 2 2 2 2 2 2 
20 GOWTHAM 26 1 1 1 3 3 1 2 1 2 2 2 2 2 
21 PAPPAN 45 1 1 2 1 2 1 2 2 2 2 2 2 2 
22 VALLINAYAGI 33 2 3 1 2 3 1 2 2 2 2 2 2 2 
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23 SELVARANI 35 2 4 2 2 2 1 3 1 2 2 2 2 2 
24 PONNAMMAL 48 2 1 1 1 3 1 1 2 2 2 2 2 2 
25 BALAKRISHNAN 40 1 1 2 4 3 1 3 1 1 1 2 2 1 
26 SELVARAJ 45 1 4 1 3 3 1 2 1 1 1 2 1 2 
27 ASHOK 23 1 1 2 1 2 1 1 2 2 1 2 2 2 
28 KARUPPASAMY 30 1 4 1 3 3 1 2 1 2 2 2 2 2 
29 JABAR HUSSAIN 45 1 3 2 3 3 1 3 1 2 2 2 2 2 
30 CHINNASAMY 47 1 1 2 3 3 1 2 1 2 1 2 2 2 
31 RAMYA 23 2 4 1 2 2 1 2 2 2 2 2 2 2 
32 KARTHIKEYAN 30 1 2 1 2 3 2 2 1 2 2 1 2 2 
33 SHANMUGAM 40 1 1 2 1 2 1 1 2 2 2 2 2 2 
34 RANI 20 2 4 1 4 3 1 3 1 1 1 2 2 1 
35 RAMAN 32 1 1 2 1 2 1 2 2 2 2 2 2 2 
36 VEERAN 62 1 3 1 2 3 1 3 1 2 2 2 2 2 
37 PANKAJ 17 1 4 1 3 3 1 3 1 2 1 2 1 2 
38 THANGARAJ 40 1 1 2 1 2 1 1 2 2 1 2 2 2 
39 AYYAMALL 55 2 1 2 2 3 1 3 1 2 2 2 2 2 
40 MANOJ 23 1 4 2 3 2 2 3 1 2 2 2 2 2 
41 DEEPAN 16 1 1 2 1 2 1 1 2 2 2 2 2 2 
42 AMMASAI 75 1 1 2 3 3 1 3 1 2 1 2 1 2 
43 MAHESHKUMAR 32 1 2 2 4 3 2 2 1 1 1 2 1 1 
44 SIVARAMAN 50 1 4 2 1 2 1 1 2 2 2 2 2 2 
45 SHAMUGALAKSHMI 35 2 3 1 2 3 1 3 1 2 2 2 2 2 
46 ANNAMAAL 56 2 1 2 3 3 1 2 1 2 2 2 2 2 
47 APPUNNI 65 1 3 2 1 1 1 1 2 2 1 2 2 2 
48 SUGANYA 17 2 4 2 4 3 1 2 1 1 1 2 2 2 
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49 VASANTHA 28 2 1 2 4 3 1 2 1 2 1 2 2 2 
50 MURUGESAN 32 1 4 2 1 2 1 2 2 2 2 2 2 2 
51 SANDEEP 20 1 1 2 3 3 1 2 1 2 1 2 2 2 
52 THARUTTAIYA 50 1 2 2 2 3 2 2 2 2 2 1 2 2 
53 THIRUMALAISAMY 68 1 3 1 3 3 1 2 2 2 2 2 2 2 
54 DEERAJKUMAR 20 1 1 2 1 2 1 1 2 2 2 2 2 2 
55 CHITRA 37 2 3 2 4 3 1 2 2 1 1 2 1 1 
56 KANNAN 29 1 2 2 1 1 2 1 2 2 2 2 2 2 
57 SEKARAN 36 1 3 1 2 3 1 2 1 2 2 2 2 2 
58 RANJAN 28 1 2 2 1 2 2 1 2 2 2 2 2 2 
59 PANEER 60 1 3 2 3 3 1 3 1 1 2 1 2 2 
60 ARUKANI 52 2 4 2 1 2 1 1 2 2 2 2 2 2 
61 BACKYIA 45 2 1 2 2 3 1 2 2 2 2 2 2 2 
62 KALPANADEVI 35 2 3 1 1 2 1 1 2 2 2 2 2 2 
63 PALRAJ 37 1 2 2 1 3 2 1 2 2 2 2 2 2 
64 MOHANRAJ 26 1 1 2 2 3 1 2 1 2 2 1 2 2 
65 RADHAKRISHNAN 34 1 3 2 1 1 1 2 2 2 2 2 2 2 
66 BABU 31 1 3 2 3 3 1 3 1 2 1 2 2 2 
67 THANGAMAAL 45 2 2 2 1 2 2 1 2 2 2 2 2 2 
68 PALANI 55 1 1 2 2 3 1 2 1 2 2 2 2 2 
69 KANDASAMY 35 1 4 1 1 2 1 2 2 2 2 2 2 2 
70 JEGANKUMAR 26 1 1 1 1 2 1 2 2 2 2 2 2 2 
71 SAMPATHKUMAR 56 1 3 2 2 3 1 2 1 2 2 2 2 2 
72 SUBRAMANI 70 1 3 2 1 2 1 1 2 2 2 2 2 2 
73 ALAMELU 40 2 1 2 4 3 1 2 1 1 1 2 1 1 
74 SAVITHRI 52 2 3 2 1 2 1 1 2 2 2 2 2 2 
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75 BANNARI 43 1 2 1 3 3 2 2 1 1 1 1 2 2 
76 SURESHKUMAR 43 1 4 2 1 2 1 1 2 2 2 2 2 2 
77 SRINIVASAN 18 1 3 2 1 3 1 1 2 2 2 2 2 2 
78 PALANIYAPPAN 52 1 1 1 4 3 1 3 1 2 1 2 1 1 
79 MEENA 43 2 3 1 2 3 1 2 2 2 1 2 2 2 
80 MARUTHACHALAM 71 1 1 1 1 2 1 2 1 2 2 2 2 2 
81 SUGANTHI 28 2 3 2 2 3 1 3 2 2 2 2 2 2 
82 SEETHA 26 2 4 2 4 3 1 3 1 1 1 2 1 2 
83 KAMALESH 28 1 2 2 2 3 2 2 1 2 1 1 2 2 
84 THOPPLAN 75 1 3 2 2 3 1 2 2 2 1 2 2 2 
85 SARAVANAN 34 1 1 2 2 3 1 2 2 2 2 2 2 2 
86 BHUVANA 32 2 3 2 2 3 1 2 1 2 2 2 2 2 
87 RAJA 65 1 4 2 1 2 1 1 2 2 2 2 2 2 
88 IQBAL 38 1 3 1 3 3 1 3 1 2 1 1 1 1 
89 VALLIYAMMAL 48 2 1 1 1 2 1 1 2 2 1 2 2 2 
90 SHEELA 34 2 3 2 2 2 1 3 2 2 1 2 2 2 
91 SANJAY MANCHI 26 1 1 2 2 3 1 2 1 2 2 2 2 2 
92 SUMATHY 34 2 3 1 2 3 1 2 1 2 1 2 2 2 
93 PARVEEN 42 2 1 2 1 2 1 1 2 2 2 2 2 2 
94 GOPAL 65 1 3 1 1 2 1 2 2 2 2 2 2 2 
95 RAMPRAKASH 34 1 2 2 4 3 2 3 1 1 1 1 1 2 
96 PONVANNAN 45 1 3 2 1 2 1 1 2 2 2 2 2 2 
97 RAJESH 19 1 2 1 2 3 2 1 1 2 1 1 2 2 
98 SELVARAJ 47 1 1 2 2 3 1 2 1 2 1 2 2 2 
99 REVATHI 61 2 1 2 3 3 1 2 1 1 1 2 2 2 
100 KUPPAN 56 1 4 1 1 1 1 1 2 2 2 2 2 2 
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